Ligand Pharmaceuticals Inc (LGND)
R&D to Revenue
23.03%
Quarterly · Period ending:
LGND R&D to Revenue
Latest reported23.03%period ending
Latest reported23.03%period ending
LGND Quarterly R&D/Revenue (0.00% → 23.03%)
Latest values, visible window
High-resolution chart · PNG
LGND r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 23.0292% | |
| 4.153% | |
| 5.8844% | |
| 18.2044% | |
| 13.7884% | |
| 110.4824% | |
| 10.3359% | |
| 10.9531% | |
| 12.8916% | |
| 19.275% | |
| 19.5296% | |
| 16.831% | |
| 25.9956% | |
| 15.1504% | |
| -93.8399% | |
| 15.6009% | |
| 16.8914% | |
| 25.1369% | |
| 25.1721% | |
| 26.1248% | |
| 18.8403% | |
| 32.4189% | |
| 31.313% | |
| 30.7135% | |
| 30.7388% | |
| 35.8584% | |
| 69.1182% | |
| 55.3934% | |
| 48.8774% | |
| 25.9613% | |
| 14.8347% | |
| 12.0075% | |
| 6.8134% | |
| 13.1898% | |
| 17.1072% | |
| 14.2592% | |
| 17.2245% | |
| 29.6341% | |
| 16.7815% | |
| 29.1642% | |
| 23.088% | |
| 13.5051% | |
| 13.5428% | |
| 14.3382% | |
| 21.7722% | |
| 27.1333% | |
| 13.9099% | |
| 20.1763% | |
| 25.3488% | |
| 19.6203% | |
| 16.1091% | |
| 18.5621% | |
| 21.1065% | |
| 21.157% | |
| 18.1591% | |
| 41.5216% | |
| 49.6343% | |
| 49.9823% | |
| 20.0835% | |
| 43.0413% | |
| 43.374% | |
| 50.9754% | |
| 80.0761% | |
| 63.253% | |
| 113.0867% | |
| 123.565% | |
| 72.4476% | |
| 125.5664% | |
| 124.7037% | |
| 110.4752% | |
| 89.297% | |
| 117.4733% | |
| 132.7435% | |
| 147.0045% | |
| 180.7972% | |
| 179.5583% | |
| 620.6383% | |
| 6,639.1489% | |
| 37.8347% | |
| 28.5177% | |
| 28.6808% | |
| 23.9775% | |
| 28.3382% | |
| 30.3189% | |
| 31.7125% | |
| 39.8405% | |
| 33.0184% | |
| 36.3254% | |
| 44.9184% | |
| 46.0286% | |
| 28.6123% | |
| 56.5675% | |
| 57.883% | |
| 71.963% | |
| 59.9129% | |
| 61.9053% | |
| 71.3816% | |
| 52.7003% | |
| 55.7612% | |
| 67.1847% |